Intestinal fxr agonism enhances glp-1 signaling to restore pancreatic beta cell functions
AssigneeThe Salk Institute for Biological Studies
InventorsSungsoon Fang, Eiji Yoshihara, Ruth T. Yu, Annette Atkins, Michael Downes, Ronald M. Evans
Life of this patent
Estimating the term…
Abstract
Disclosed are embodiments of a method of treating or preventing latent autoimmune diabetes of adults (LADA) in a subject. Such embodiments include administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or farnesoid X receptor (FXR) agonist compounds, thereby activating FXR receptors in the intestines, and treating or preventing latent autoimmune diabetes of adults (LADA) in the subject.
Claims19
A method of treating or preventing latent autoimmune diabetes of adults (LADA) in a subject, comprising administering to a gastrointestinal tract of the subject a therapeutically effective amount of one or more farnesoid X receptor (FXR) agonists, thereby activating FXR receptors in the intestine of the subject and treating or preventing LADA in the subject.
Dependencies are inferred from the claim text.